65th ASH Annual Meeting 2023 (San Diego, USA) **–**
Overview of CML related sessions

Timings in Pacific Time (PT)

Time slots	Sessions
Satellite Symposia	
Dec 8 (Friday) 3.00 – 6.00 p.m. Pacific Ballroom Salons 24-26 (Mariott Marquis San Diego Marina)	**Satellite Symposium**: Putting your stamp on the next generation of care in CML: Improving outcomes from frontline to R/R treatment settings Sponsor: Ascentage Pharma and Novartis Pharmaceuticals Corporation Chair: Jorge Cortes (Augusta University) Speakers: • Andreas Hochhaus (Universitätsklinikum Jena) • Amanda Rodriguez (Moffitt Cancer Center)
Education Program	
Dec 10 (Sunday) 4.30 – 5.45 p.m. San Diego Ballroom AB (Mariott Marquis San Diego Marina)	**Education Session**: How do we tackle remaining challenges in CML? Chair: Naranie Shanmuganathan (Royal Adelaide Hospital) Program: • Beyond chronic phase CML: de novo and transformed (Naranie Shanmunagathan, Adelaide, Australia) • Resistance mutations in CML and how we approach them (Simona Soverini, Bologna, Italy) • Atypical CML diagnosis and treatment (Massimo Breccia, Rome, Italy)
Oral Sessions	
Dec 10 (Sunday) 9.30 – 11.00 a.m. Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego	**Oral Session:** Chronic Myeloid Leukemia: Clinical and Epidemiological Treatment-free Remission and Prognostication Moderators: • François-Xavier Mahon (Université Bordeaux 2) • Mhairi Copland (Gartnavel General Hospital) Program: • 9.30 a.m.: Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Time slots	Sessions
Marina)	(Nicolini FE) (445) • 9.45 a.m.: Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial (Hochhaus A et al.) (446) • 10.00 a.m.: Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML (Branford S et al.) (447) • 10.15 a.m.: Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML (Millot F et al.) (448) • 10.30 a.m.: Impact of Mutations in Blood Cancer–Related Genes on Clinical Outcomes in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Tyrosine Kinase Inhibitors (TKIs) in the Ascembl Trial (Branford S et al.) (449) • 10.45 a.m.: With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study (Hochhaus A.) (450)
Dec 11 (Monday) 2.45 – 4.15 p.m. Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)	**Oral Session:** Chronic Myeloid Leukemia: Clinical and Epidemiological Novel Therapeutic Approaches Moderators • Carmen Fava (Department of Clinical and Biological Sciences, University of Turin) • Ehab L. Atallah (Medical College of Wisconsin) Program: • 2.45 p.m.: Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study (Yeung DT et al.) (865) • 3.00 p.m.: Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study (Hughes TP et al.) (866) • 3.15 p.m.: Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study (Jiang Q et al.) (867)

Time slots	Sessions
	• 3.30 p.m.: Asciminib (ASC) in Combination with Imatinib (IMA), Nilotinib (NIL), or Dasatinib (DAS) May be a Potential Treatment (Tx) Option in Patients (Pts) with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase (Ph+ CML-CP/AP): Final Results from the Asciminib Phase 1 Study (Cortes J et al.) (868) • 3.45 p.m.: Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study 8 (Jiang Q et al.) (869) • 4.00 p.m.: Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML) (Haddad FG et al.) (870)
Dec 11 (Monday) 2.45 – 4.15 p.m. Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)	**Oral Session:** Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Lineage Tracing and Novel Target Discovery Moderators: • Linda Resar (John Hopkins University SOM) • Bethan Psaila (University of Oxford) Program: • 3.30 p.m.: Nutrient-Sensitising Drug Repurposing Screen Identifies Lomerizine As a Mitochondrial Metabolism Inhibitor in Chronic Myeloid Leukaemia (Helgason V et al.) (862)
Poster Sessions	
Dec 9 (Saturday) 5.30 – 7.30 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Chronic Myeloid Leukemia Clinical and Epidemiological: Poster I Poster: • 1795: Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial (Pérez-Lamas L et al.) • 1796: Analysis the Relationship between Clonal Hematopoiesis and Cardiovascular Events in Chronic Myeloid Leukemia Based on Next-Generation Sequencing Technology (Xu N et al.) • 1797: Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (Chen S et al.) • 1798: Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Time slots	Sessions
	(Ph+ ALL) (Jabbour E et al.) • 1799: Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study (Nicolini FE et al.) • 1800: Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study (Legros L et al.) • 1801: Dynamic Single-Cell RNA-Seq Reveals Mechanism of Selinexor-Resistance in Chronic Myeloid Leukemia (Sun Z et al.) • 1802: The Outcomes of Pregnancies in Japanese Patients with CML in the TKI Era; A Result of Nationwide Survey (Kondo T et al.) • 1803: The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia (Chelycheva E et al.) • 1804: Is the Prognosis of People with Chronic Myeloid Leukaemia Presenting in Accelerated Phase Always Worse Compared with People Presenting in Chronic Phase? (Yang S et al.) • 1805: Highly Sensitive Chip-Based Digital PCR Platform for Quantitative Detection of BCR::ABL1 Transcripts throughout CML Treatment (Song HW et al.) • 1806: Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia (Lee S et al.) • 1807: TKI Dose Optimization Based on Therapeutic Drug Monitoring TDM) with Encouraging Outcomes and Well-Tolerated for Chronic Myeloid Leukaemia Patients (Xu N et al.) • 1808: Successful Treatment-Free Remission in Low- and Middle-Income Countries (Radich JP et al.) • 1809: Real-World Evaluation of Treatment Patterns and Clinical Outcomes Among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Asciminib in US Clinical Practice (Atallah EL et al.) • 1810: Prospective Assessment of Co-Morbidities and Framingham Risk Score in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients and Its Impact on Clinical Outcomes Following Frontline TKI Therapy: Toronto CML Genomic Alliance in Greater Toronto Area & Ontario (TCGA-GTA) (Chiu M et al.) • 1811: Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study (Cavazzini F et al.)

Time slots	Sessions
Dec 9 (Saturday) 5.30 – 7.30 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I Poster: • 1785: Loss of Function of SETD2 Tumor Suppressor in Chronic Myeloid Leukemia (CML) Progenitors Fosters Genomic Instability and Enhances Clonogenic Potential (De Santis S et al.) • 1786: Role of *Lama4* Expression in Bone Marrow Niche for the Progression and Treatment Response of Chronic Myeloid Leukemia (Mansson A et al.)
Dec 10 (Sunday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Chronic Myeloid Leukemia Clinical and Epidemiological: Poster II Poster: • 3164: Long-Term Results from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (Cortes J et al.) • 3165: 3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients (Malagola M et al.) • 3166: Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era (Hornak T et al.) • 3167: A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia (Zhang XS et al.) • 3168: The Use of 2nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2nd Generation TKIs (Giai V et al.) • 3169: International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation (Pane F et al.) • 3170: Whole Genome and Transcriptome Sequencing of 21 Paired Chronic and Blast Phase CML Cases: Acquisition of Genomic Alterations, Changes in the Transcriptomic Profiles and Occurrence of B-Cell Receptor Rearrangements (Haferlach C et al.) • 3171: Evaluating Effectiveness and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia in (CML-CP) without Optimal Response (Warning, Failure) to Imatinib or/and Dasatinib (Weiming L et al.) • 3172: Asciminib (ASC) Once-Daily (QD) Dosing Demonstrates

Time slots	Sessions
	Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Results from the ASC in Monotherapy 4 CML (AIM4CML) Study in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (Andorsky D et al.) • 3173: Outcomes of Adolescents and Young Adult Patients with Chronic Myeloid Leukemia in the Era of Second-Generation TKIs and Treatment-Free Remission (Schoenbeck K et al.) • 3174: Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in "Real-Life" Settings: A Population-Based Study Using a Nationwide Claim Database (Nicolini FE et al.) • 3175: Flumatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: An Open-Label, Multi-Center Study (Xu N et al.) • 3176: Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study (Brucelli C et al.) • 3177: Outcomes of Chronic Myeloid Leukemia Patients after Therapeutic Failure to Asciminib, a Multicenter Observational Study (Pérez-Lamas L et al.) • 3178: On the Children Side. Overview of 194 Outcomes from Gimema Registry of Conception/Pregnancy in Chronic Myeloid Leukemia (CML) (Abruzzese E et al.) • 3179: Lower-Initiating Dose of Bosutinib for Resistant or Intolerant to Prior Therapy Chronic Myeloid Leukemia Patients (BOGI trial): A Single-Arm, Multicenter, Phase II Trial (Ureshino H et al.) • 3180: Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients (Bernardi S et al.)
Dec 10 (Sunday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II Poster: • 3146: Single-Cell Analysis of Immune Recognition in Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitor Discontinuation (Huuhtanen J et al) • 3151: Multiomic Single-Cell Analysis Identifies Von Willebrand Factor and TIM3-Expressing *BCR-ABL1*+ Chronic Myeloid Leukemia Stem Cells (Nilsson MS et al) • 3152: Acquired microRNA-142 Deficit Drives Escape Mechanisms of Anti-Leukemic Surveillance during Blast Crisis Transformation of Chronic Myeloid Leukemia (CML) (Chen F et al.)

Time slots	Sessions
	• 3154: Uncovering the Transcriptional Landscape of CML Development and Therapeutic Interventions Via State-Transition Modeling (Frankhouser D et al.) • 3159: Single Cell Analysis of Genes Involved in Asymmetric Hematopoietic Stem Cell (HSC) Division in Chronic Myeloid Leukemia (CML) : Evidence of the Regulation of Tetraspanin CD63 during Leukemia Progression (Turhan A et al.)
Dec 11 (Monday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Chronic Myeloid Leukemia Clinical and Epidemiological: Poster III Poster: • 4534: Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study (Iurlo A et al.) • 4535: Benefit of TKI-Treatment in CML after Failing Molecular or Cytogenetic Milestones (Hehlmann R et al.) • 4536: Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population (Mauro M et al.) • 4537: The Real-World Outcomes of Ponatinib in 724 Patients with CML and Ph+ ALL : A Post-Marketing Surveillance Study with a Special Interest in Arterial Occlusive Events in Japan (Takahashi N et al.) • 4538: Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study (Xu N et al.) • 4539: ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry (Kohlbrenner K et al.) • 4540: Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study (Sloma I et al.) • 4541: Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP) (Castagnetti F et al.) • 4542: To Study Outcomes in Young CML Treated with TKI. a Registry

Time slots	Sessions
	Data from Hematological Cancer Consortium (HCC) of India (Mishra K et al.) • 4543: Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission (Perusini MA et al.) • 4544: Somatic Mutations in Cancer-Related Genes Were Observed More Frequently in AYA CML Patients Compared to Elderly at Diagnosis, Whereas the Frequency Was Markedly Higher in Elderly Patients during TKI Treatment (Krizkova J et al.) • 4545: Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival (Huang L et al.) • 4546: Treatment Free Remission (TFR) "for" Pregnancy. Overview and Outcome of Pregnancies Reported in the Italy-Tfr Registry (Abruzzese E et al.) • 4547: Identification of Multivariable microRNA and Clinical Biomarkers Panels to Predict Imatinib Response in Chronic Myeloid Leukemia at Diagnosis (Wu A et al.) • 4548: Association and Significance of Allostatic Load with Outcomes of Patients with Chronic Myeloid Leukemia (CML) (Sharara M et al.) • 4549: Chronic Myeloid Leukemia in Adolescents and Young Adults: A SEER-Based Analysis of Characteristics and Survival Outcomes of 1565 Patients (Uche IN et al.) • 4550: 3rd-Generation Tyrosine Kinase-Inhibitors and Azacitidine Are Safe and Effective in Myeloid Blast-Phase Chronic Myeloid Leukaemia and Result in a High Proportion of Subjects in 2nd Chronic Phase Able to Receive a Transplant (Bao M et al.)
Dec 11 (Monday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Myeloproliferative Syndromes and Chronic Myeloid leukemia: Basic and Translational: Poster III Poster: • 4514: Chimeric Antigen-Receptor (CAR)-Engineered Natural Killer (NK) Cells Targeting Chronic Myeloid Leukemia (CML) Blast Crisis (Turhan A et al.) • 4531: New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison (Gupta G et al.)

Time slots	Sessions
Dec 11 (Monday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Acute Myeloid Leukemia: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis: Poster III Poster: • 4334: Multiomic Single-Cell Sequencing May Distinguish BCR-ABL-Mutated Acute Myeloid Leukemia (AML) from Blast Crisis Chronic Myelogenous Leukemia (BC-CML) (Kennedy VE et al)
Dec 11 (Monday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Chemical Biology and Experimental Therapeutics: Poster III Poster: • 5012: A Novel BCR-ABL1 Degrader, Ubx-362, Can Overcome Resistance By BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia (Seul Lim Y et al.)
Dec 11 (Monday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Health Services and Quality Improvement: Myeloid Malignancies: Poster III Poster: • 5098: Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US) (Kota VK et al.)
Dec 11 (Monday) 6.00 – 8.00 p.m. Hall G-H (San Diego Convention Center)	**Poster Session:** Outcomes Research: Myeloid Malignancies: Poster III Poster: • 5190: Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US) (Kota V et al.)